Annals of the Rheumatic Diseases, ‎0003-4967

Journal

1 - 10 out of 164Page size: 10

Publications

  1. 2021
  2. Accepted/In press

    EULAR points to consider for conducting clinical trials and observational studies in individuals at-risk of rheumatoid arthritis

    Karim Raza, , , , & , 24 Jul 2021, (Accepted/In press) In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journal › Article › peer-review

  3. Published

    Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids

    Adam Croft, Joana Campos, Amy Naylor, Angela Taylor, Myriam Chimen, , Gareth Lavery, Karim Raza & Rowan Hardy, Feb 2021, In: Annals of the Rheumatic Diseases. 80, 2, p. 250-260 11 p.

    Research output: Contribution to journal › Article › peer-review

  4. 2020
  5. Published

    Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

    Caroline Gordon, 25 Jun 2020, In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journal › Letter › peer-review

  6. Published

    PERSPECTIVES ON APPROACHES TO PREDICT THE DEVELOPMENT OF RHEUMATOID ARTHRITIS: A QUANTITATIVE ASSESSMENT OF PATIENTS AND THEIR FIRST DEGREE RELATIVES

    Gwenda Simons, , , Peter Nightingale, Karim Raza & M Falahee, 2 Jun 2020, In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journal › Abstract › peer-review

  7. Published

    PREDICTING RHEUMATOID ARTHRITIS USING THE SYMPTOMS IN PERSONS AT RISK OF RHEUMATOID ARTHRITIS (SPARRA) QUESTIONNAIRE

    M Falahee, , , , Karim Raza & , 2 Jun 2020, In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journal › Abstract › peer-review

  8. Published

    SAT0186 Developing predictors of global BILAG treatment response in patients with Lupus Nephritis: more lessons from the Aspreva Lupus Management Study group (ALMS) data

    2 Jun 2020, In: Annals of the Rheumatic Diseases. 79, Suppl 1, p. 1034-1035 2 p.

    Research output: Contribution to journal › Abstract › peer-review

  9. Accepted/In press

    Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

    Lorraine Harper, Apr 2020, (Accepted/In press) In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journal › Article › peer-review

  10. Published

    Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach

    Caroline Gordon & 14 others, , , , , , , , , , , , , & , Mar 2020, In: Annals of the Rheumatic Diseases. 79, 3, p. 356-362 7 p.

    Research output: Contribution to journal › Article › peer-review

  11. Accepted/In press

    Disruptive Innovation in Rheumatology; New Networks of Global Public-Private Partnerships are Needed to Take Advantage of Scientific Progress

    Christopher Buckley, 26 Feb 2020, (Accepted/In press) In: Annals of the Rheumatic Diseases. 79, 5

    Research output: Contribution to journal › Article › peer-review

  12. Published

    Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care

    Raymond Oppong, , , , , , , Sue Jowett, , , , , , , & , Feb 2020, In: Annals of the Rheumatic Diseases. 79, 2, p. 276-284 9 p.

    Research output: Contribution to journal › Article › peer-review

Previous 1 2 3 4 5 6 7 8 ...17 Next